As a result, inhibition of AMPK phosphorylation by chronic alcohol consumption increases SREBP-1, PPAR-γ, and FAS expression, contributing to the development of hepatic steatosis, so AMPK can be considered a focus for the treatment of AFLD [4]. The gene discussed is SREBF1; the disease is fatty liver disease.